Safety and clinical usage of newcastle disease virus in cancer therapy
- PMID: 22131816
- PMCID: PMC3205905
- DOI: 10.1155/2011/718710
Safety and clinical usage of newcastle disease virus in cancer therapy
Erratum in
-
Corrigendum to "Safety and Clinical Usage of Newcastle Disease Virus in Cancer Therapy".Biomed Res Int. 2017;2017:4529437. doi: 10.1155/2017/4529437. Epub 2017 Dec 3. Biomed Res Int. 2017. PMID: 29333441 Free PMC article.
Abstract
Newcastle disease virus (NDV) is an avian virus that causes deadly infection to over 250 species of birds, including domestic and wild-type, thus resulting in substantial losses to the poultry industry worldwide. Many reports have demonstrated the oncolytic effect of NDV towards human tumor cells. The interesting aspect of NDV is its ability to selectively replicate in cancer cells. Some of the studies have undergone human clinical trials, and favorable results were obtained. Therefore, NDV strains can be the potential therapeutic agent in cancer therapy. However, investigation on the therapeutic perspectives of NDV, especially human immunological effects, is still ongoing. This paper provides an overview of the current studies on the cytotoxic and anticancer effect of NDV via direct oncolysis effects or immune stimulation. Safety of NDV strains applied for cancer immunotherapy is also discussed in this paper.
Similar articles
-
Oncolytic therapy and gene therapy for cancer: recent advances in antitumor effects of Newcastle disease virus.Discov Med. 2020 Jul-Aug;30(159):39-48. Discov Med. 2020. PMID: 33357361 Review.
-
Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.Expert Opin Biol Ther. 2015;15(12):1757-71. doi: 10.1517/14712598.2015.1088000. Epub 2015 Oct 5. Expert Opin Biol Ther. 2015. PMID: 26436571 Review.
-
Newcastle disease virus: a promising agent for tumour immunotherapy.Clin Exp Pharmacol Physiol. 2012 Aug;39(8):725-30. doi: 10.1111/j.1440-1681.2011.05662.x. Clin Exp Pharmacol Physiol. 2012. PMID: 22211810 Review.
-
Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.Methods Mol Biol. 2012;797:177-204. doi: 10.1007/978-1-61779-340-0_13. Methods Mol Biol. 2012. PMID: 21948477
-
Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.J Virol. 2010 Apr;84(8):3835-44. doi: 10.1128/JVI.01553-09. Epub 2010 Feb 10. J Virol. 2010. PMID: 20147405 Free PMC article.
Cited by
-
Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?J Cancer. 2015 Jan 15;6(3):203-17. doi: 10.7150/jca.10640. eCollection 2015. J Cancer. 2015. PMID: 25663937 Free PMC article. Review.
-
Syncytia Formation in Oncolytic Virotherapy.Mol Ther Oncolytics. 2019 Oct 1;15:131-139. doi: 10.1016/j.omto.2019.09.006. eCollection 2019 Dec 20. Mol Ther Oncolytics. 2019. PMID: 31890866 Free PMC article. Review.
-
Oncolytic Newcastle disease virus expressing the co-stimulator OX40L as immunopotentiator for colorectal cancer therapy.Gene Ther. 2023 Feb;30(1-2):64-74. doi: 10.1038/s41434-021-00256-8. Epub 2021 Oct 4. Gene Ther. 2023. PMID: 34602608
-
Enhanced Oncolytic Potential of Engineered Newcastle Disease Virus Lasota Strain through Modification of Its F Protein Cleavage Site.Microorganisms. 2024 Oct 8;12(10):2029. doi: 10.3390/microorganisms12102029. Microorganisms. 2024. PMID: 39458338 Free PMC article.
-
Viruses in cancer treatment.Clin Transl Oncol. 2013 Mar;15(3):182-8. doi: 10.1007/s12094-012-0951-7. Epub 2012 Nov 10. Clin Transl Oncol. 2013. PMID: 23143950 Review.
References
-
- World Health Organization (WHO) 2010, http://www.who.int/cancer/en/. Assessed 2010 August 15.
-
- National Cancer Registry (NCR) Malaysian Cancer Statistics—Data and Figure Peninsular Malaysia 2006. Malaysia, Kuala Lumpur: National Cancer Registry; 2006.
-
- Blomqvist C, et al. FEC (5-fluorouracil-epirubicin-cyclophosphamide) monthly versus FEC weekly in metastasis breast cancer. First results of a randomized trial. Acta Oncologica. 1996;31:231–236. - PubMed
-
- Kasuya H, Pawlik TM, Mullen JT, et al. Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen. Cancer Research. 2004;64(7):2561–2567. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources